ArticleFertility and sterility2017
Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy.
Article in Fertility and sterility, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Trial
- Restoration of spermatogenesis in a male with prolactinoma-induced hypogonadotropic hypogonadism using follitropin delta and recombinant choriogonadotropin alfa: a case report.Journal of assisted reproduction and genetics · 2026Article
- Preserving spermatogenesis in testosterone deficiency: innovations in replacement and stimulatory therapies.Translational andrology and urology · 2025Review
- Testosterone replacement therapy and spermatogenesis in reproductive age men.Nature reviews. Urology · 2025Review
- [Restoration of ejaculate quality following androgen replacement and combined therapy for hypogonadism].Problemy endokrinologii · 2025Observational
- Review
- Therapeutic effects of a pulsatile GnRH pump on adult male patients with congenital hypogonadotropic hypogonadism (CHH): a retrospective study.Translational andrology and urology · 2025Article
- Is combined androgen and gonadotropin therapy a viable harm reduction strategy for men using high-dose exogenous androgens who are interested in family building?F&S reports · 2025Article
- Efficacy of human chorionic gonadotropin hormone in restoring spermatogenesis in men using non-prescribed androgens: a retrospective analysis of real-world data.F&S reports · 2025Article
- Clinician's guide to the management of azoospermia induced by exogenous testosterone or anabolic-androgenic steroids.Asian journal of andrology · 2025Review
- Nonobstructive azoospermia: an etiologic review.Asian journal of andrology · 2025Review
- Letrozole and Crocin: Protecting Leydig Cells and Modulating Androgen Receptor and CYP19 Gene Expression in Busulfan-Induced Azoospermia.Animals : an open access journal from MDPI · 2025Article
- A Current Perspective on Delayed Puberty and Its ManagementJournal of clinical research in pediatric endocrinology · 2024Review
- Male Fertility as a Proxy for Health.Journal of clinical medicine · 2024Review
- Management of Male Fertility in Hypogonadal Patients on Testosterone Replacement Therapy.Medicina (Kaunas, Lithuania) · 2024Review
- Fertility outcomes in men with prior history of anabolic steroid use.Fertility and sterility · 2023Article
- Male infertility.Nature reviews. Disease primers · 2023Review
- Article
- Comparison of Intratesticular Testosterone between Men Receiving Nasal, Intramuscular, and Subcutaneous Pellet Testosterone Therapy: Evaluation of Data from Two Single-Center Randomized Clinical Trials.The world journal of men's health · 2023Article
- Treatment progress of cryptozoospermia with Western Medicine and traditional Chinese medicine: A literature review.Health science reports · 2023Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
objectiveTo determine factors that influence sperm recovery after T-associated infertility.
designClinical retrospective study.
settingAcademic male-infertility urology clinic. PATIENT(S): Sixty-six men who presented with infertility after T use. INTERVENTION(S): T cessation and combination high-dose hCG and selective estrogen modulator (SERM) therapy. MAIN OUTCOME MEASURE(S): Whether patients successfully achieved or failed to achieve a total motile count (TMC) of greater than 5 million sperm within 12 months of T cessation and initiation of therapy. RESULT(S): A TMC of greater than 5 million sperm was achieved by 46 men (70%). Both increased age and duration of T use directly correlated with time to sperm recovery at both 6 and 12 months of hCG/SERM therapy. Age more consistently limited sperm recovery, while duration of T use had less influence at 12 months than at 6 months. Only 64.8% of azoospermic men achieved a TMC greater than 5 million sperm at 12 months, compared with 91.7% of cryptozoospermic men, yet this did not predict a failure of sperm recovery. CONCLUSION(S): Increasing age and duration of T use significantly reduce the likelihood of recovery of sperm in the ejaculate, based on a criterion of a TMC of 5 million sperm, at 6 and 12 months. Physicians should be cautious in pursuing long-term T therapy, particularly in men who still desire fertility. Using these findings, physicians can counsel men regarding the likelihood of recovery of sperm at 6 and 12 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.